Alteration of panel-reactive antibodies following treatment with either atorvastatin or low-dose mycophenolate mofetil in sensitized hemodialysis patients.
Ghorbani A, Shahbazian H, et al.Iranian Journal of Kidney Diseases, 5(5): 342-346, 2011.
Aims
To compare the effect of low-dose mycophenolate mofetil (MMF) with atorvastatin on panel-reactive antibodies (PRA) in sensitized hemodialysis patients waiting for kidney transplantation.
Interventions
Two months treatment with atorvastatin versus low-dose MMF.
Participants
40 patients who had been on haemodialysis for approximately 4 years and were highly sensitized as defined by having a PRA of greater than 40%.
Outcomes
Main outcome was level of PRA. Other outcomes included serious adverse events and patients death rate during the study period.
Follow-up
2 months
CET Conclusions
At the end of the two months there was no change in the PRA of the patients treated with MMF whereas there was a significant reduction in those treated with atorvastatin. No data is given on titres of the antibodies and results can only be regarded as interesting at this point in time.
Data analysis
Per protocol analysis
Trial registration
Not reported